Merck KGaA Withdraws Application for Cancer Drug

by Bidita Debnath on  September 19, 2012 at 12:05 PM Cancer News   - G J E 4
On Tuesday, German pharmaceuticals maker Merck KGaA is withdrawing its application for its drug Erbitux used to treat patients with lung cancer.
 Merck KGaA Withdraws Application for Cancer Drug
Merck KGaA Withdraws Application for Cancer Drug

Merck said in a statement it had decided to "voluntarily withdraw the marketing authorisation application to the European Medicines Agency" for Erbitux to be used to treat patients with advanced or metastatic non-small cell lung cancer.

The decision was "based on feedback from European regulatory authorities, indicating that further data would be required," the statement said.

It would not affect, however, "the proven utility of Erbitux in its already approved indications in metastatic colorectal cancer and head and neck cancer," Merck insisted.

"We are disappointed that we have not been able to move forward with the filing but it has become apparent that further data will be required to support the clinical utility of Erbitux in this specific population," said Merck's head of drug development, Annalisa Jenkins.

Already in July, Merck KGaA had said that phase III clinical trials of Erbitux for treatment of gastric cancer drug had shown no benefits of the drug for patients.

The news hit Merck KGaA shares which were showing a loss of 1.24 percent at 93.67 euros in mid-morning trade on the Frankfurt stock exchange in a generally softer market.

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All